Survival prediction in patients with resectable colorectal liver metastases: Clinical risk scores and tumor response to chemotherapy

被引:16
作者
Xu, Da [1 ]
Liu, Xiao-Feng [2 ]
Yan, Xiao-Luan [1 ]
Wang, Kun [1 ]
Xing, Bao-Cai [1 ]
机构
[1] Peking Univ, Beijing Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Sch Oncol,Minist Educ,Hepatopancreatobiliary Surg, 52 Fucheng Rd, Beijing 100142, Peoples R China
[2] Peking Univ, Hlth Sci Ctr, Sch Basic Med Res, Dept Cell Biol, Beijing 100191, Peoples R China
关键词
clinical risk score; colorectal liver metastasis; neo-adjuvant chemotherapy; prognostic factor; survival; tumor response; LONG-TERM SURVIVAL; HEPATIC METASTASES; NEOADJUVANT CHEMOTHERAPY; RESCUE SURGERY; CANCER; RESECTION; CETUXIMAB; TRIAL; KRAS; MANAGEMENT;
D O I
10.3892/ol.2017.7191
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Clinical risk scores and response to pre-operative chemotherapy are prognostic factors of colorectal liver metastases. The aim of the present study was to evaluate the effectiveness of combining these factors to predict patient survival and to select patients for curative therapy. The study included 189 patients who underwent hepatectomy following neo-adjuvant chemotherapy, for initially resectable colorectal liver metastases, between January 2005 and December 2015. Patients were stratified into four sub-groups: A1-2, low clinical risk scores with/without a response to pre-operative chemotherapy; and B1-2, high clinical risk scores with or without a response to pre-operative chemotherapy. Treatment and survival data were analysed. Survival was significantly longer in patients with low clinical risk scores and a response to pre-operative chemotherapy; these factors were confirmed as independent prognostic factors by multivariate analysis. Combining clinical risk score and chemotherapy response classification, patient survival was significantly longer for groups A1-2/B1 compared with for group B2, in which only 10.2% of patients were alive after 5 years. Of those with no response to first-line chemotherapy, survival was significantly longer in patients who responded to second-line chemotherapy. A combined clinical risk score and chemotherapy response classification may aid in identifying suitable candidates for potentially curative therapy.
引用
收藏
页码:8051 / 8059
页数:9
相关论文
共 50 条
  • [1] Neoadjuvant chemotherapy improves overall survival in resectable colorectal liver metastases patients with high clinical risk scores-- A retrospective, propensity score matching analysis
    Chen, Feng-Lin
    Wang, Yan-Yan
    Liu, Wei
    Xing, Bao-Cai
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [2] Clinical risk scores in the current era of neoadjuvant chemotherapy for colorectal liver metastases
    Kumar, Rohan
    Dennison, Ashley R.
    Robertson, Vaux
    Jones, Michael J.
    Neal, Christopher P.
    Garcea, Giuseppe
    ANZ JOURNAL OF SURGERY, 2018, 88 (1-2) : E16 - E20
  • [3] The survival benefit of neoadjuvant chemotherapy for resectable colorectal liver metastases with high tumor burden score
    Yonekawa, Yoshihiko
    Uehara, Kay
    Mizuno, Takashi
    Aiba, Toshisada
    Ogura, Atsushi
    Mukai, Toshiki
    Yokoyama, Yukihiro
    Ebata, Tomoki
    Kodera, Yasuhiro
    Nagino, Masato
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2021, 26 (01) : 126 - 134
  • [4] Impact of Neoadjuvant Chemotherapy on Clinical Risk Scores and Survival in Patients with Colorectal Liver Metastases
    Wimmer, Kerstin
    Schwarz, Christoph
    Szabo, Carmen
    Bodingbauer, Martin
    Tamandl, Dietmar
    Mittlboeck, Martina
    Kaczirek, Klaus
    ANNALS OF SURGICAL ONCOLOGY, 2017, 24 (01) : 236 - 243
  • [5] Effect of Neoadjuvant Chemotherapy in Patients with Resectable Colorectal Liver Metastases
    Zhu, Dexiang
    Zhong, Yunshi
    Wei, Ye
    Ye, Lechi
    Lin, Qi
    Ren, Li
    Ye, Qinghai
    Liu, Tianshu
    Xu, Jianmin
    Qin, Xinyu
    PLOS ONE, 2014, 9 (01):
  • [6] Impact of Neoadjuvant Chemotherapy on Clinical Risk Scores and Survival in Patients with Colorectal Liver Metastases
    Kerstin Wimmer
    Christoph Schwarz
    Carmen Szabo
    Martin Bodingbauer
    Dietmar Tamandl
    Martina Mittlböck
    Klaus Kaczirek
    Annals of Surgical Oncology, 2017, 24 : 236 - 243
  • [7] The Role of Preoperative Chemotherapy in Patients with Resectable Colorectal Liver Metastases
    Benoist, Stephane
    Nordlinger, Bernard
    ANNALS OF SURGICAL ONCOLOGY, 2009, 16 (09) : 2385 - 2390
  • [8] Impact of homogeneous pathologic response to preoperative chemotherapy in patients with multiple colorectal liver metastases
    Sabbagh, Charles
    Chatelain, Denis
    Attencourt, Christophe
    Joly, Jean-Paul
    Chauffert, Bruno
    Cosse, Cyril
    Regimbeau, Jean-Marc
    WORLD JOURNAL OF GASTROENTEROLOGY, 2017, 23 (45) : 8027 - 8034
  • [9] Multicentre study of perioperative versus adjuvant chemotherapy for resectable colorectal liver metastases
    Allard, M-A
    Nishioka, Y.
    Beghdadi, N.
    Imai, K.
    Gelli, M.
    Yamashita, S.
    Kitano, Y.
    Kokudo, T.
    Yamashita, Y-, I
    Cunha, A. Sa
    Vibert, E.
    Elias, D.
    Cherqui, D.
    Goere, D.
    Adam, R.
    Baba, H.
    Hasegawa, K.
    BJS OPEN, 2019, 3 (05): : 678 - 686
  • [10] The survival benefit of neoadjuvant chemotherapy for resectable colorectal liver metastases with high tumor burden score
    Yoshihiko Yonekawa
    Kay Uehara
    Takashi Mizuno
    Toshisada Aiba
    Atsushi Ogura
    Toshiki Mukai
    Yukihiro Yokoyama
    Tomoki Ebata
    Yasuhiro Kodera
    Masato Nagino
    International Journal of Clinical Oncology, 2021, 26 : 126 - 134